Fairness opinions › Acquirers
KKR: healthcare acquisitions with fairness opinions
3 public-company targets, 2017-2026, $17B combined enterprise value. The multiples KKR paid and the banker analyses behind each target board's recommendation.
Deals
3
Median EV / EBITDA paid
10.0x
Median EV / revenue paid
1.16x
| Announced | Target | Acquirer | Segment | EV | EV/EBITDA | EV/Rev | DCF rate | Fairness opinion |
|---|---|---|---|---|---|---|---|---|
| 2026-08-03 | Integer | KKR | Medical Devices and Supplies | $5.7B | 14.6x | 3.09x | 9.0%–10.0% | |
| 2018-06-11 | Envision Healthcare Holdings | KKR | Physician Groups | $9.9B | 10.0x | 1.16x | 8.0%–9.0% | J.P. Morgan, Evercore, Guggenheim Securities |
| 2017-08-02 | PharMerica | KKR | Pharmacy / Infusion | $1.4B | 9.6x | 0.60x | 8.0%–9.0% | UBS, BofA Securities |